BLAINJECTIONINJECTABLEPriority Review
Approved
Dec 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 6h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LUNSUMIO (mosunetuzumab) is a bispecific antibody that bridges B cells and T cells to enable immune-mediated destruction of cancer cells. It is approved for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. The drug represents a novel immunotherapy approach leveraging dual-targeting mechanisms.
Peak
Product is in peak commercial phase with moderate competitive pressure (30%), indicating active team expansion and marketing investment in the hematologic oncology space.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Phase 2 Study Of Mosunetuzumab In Patients With Chronic Lymphocytic Leukemia With Positive MRD
Started Jul 2026
30 enrolled
Lymphocytic Leukemia
Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)
Started Jun 2026
25 enrolled
Waldenstrom Macroglobulinemia
A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
Started May 2026
30 enrolled
LupusSystemic Lupus ErythematosusLupus Nephritis
Trial to Evaluate Efficacy and Safety of Subcutaneous Mosunetuzumab in Previously Untreated Low Tumor Burden Follicular Lymphoma .
Started Jan 2026
40 enrolled
Follicular Lymphoma
Mosunetuzumab for CLL MRD Clearance
Started Nov 2025
40 enrolled
LeukemiaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma+1 more
Worked on LUNSUMIO at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.